Search
Coronavirus-Like Particle COVID-19 Vaccine
go.drugbank.com/drugs/DB15852ExperimentalThe vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. … The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Polycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnIt is insoluble in water, dilute acids, and dilute alkali.
Categories: Compounds used in a research, industrial, or household settingPadeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]
Categories: Sensitizers Used in Photodynamic/radiation TherapyRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawnUntil the last review in 2015, this drug is still available in the market.[L1113] … [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.
Categories: Compounds used in a research, industrial, or household settingDaclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnin de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons … The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.
Products: Zinbryta PenEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigationalEtuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnThe organism was named _Streptomyces aureofaciens_ due to its gold-hued color. … He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri.